Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration.
Jorge Antonio Gutierrez,Sunil V. Rao,William Schuyler Jones,Eric A. Secemsky,Aaron W. Aday,Lin Gu,Ryan D. Schulteis,Mitchell W. Krucoff,Roseann White,Ehrin J. Armstrong,Subhash Banerjee,Shirling Tsai,Manesh R. Patel,Rajesh V. Swaminathan
DOI: https://doi.org/10.1161/JAHA.120.018149
IF: 6.106
2021-02-10
Journal of the American Heart Association
Abstract:BACKGROUND The long‐term safety of paclitaxel‐coated devices (PCDs; drug‐coated balloon or drug‐eluting stent) for peripheral endovascular intervention is uncertain. We used data from the Veterans Health Administration to evaluate the association between PCDs, long‐term mortality, and cause of death. METHODS AND RESULTS Using the Veterans Administration Corporate Data Warehouse in conjunction with International Classification of Diseases, Tenth Revision ( ICD‐10 ) Procedure Coding System, Current Procedural Terminology, and Healthcare Common Procedure Coding System codes, we identified patients with peripheral artery disease treated within the Veterans Administration for femoropopliteal artery revascularization between October 1, 2015, and June 30, 2019. An adjusted Cox regression, using stabilized inverse probability–weighted estimates, was used to evaluate the association between PCDs and long‐term survival. Cause of death data were obtained using the National Death Index. In total, 10 505 patients underwent femoropopliteal peripheral endovascular intervention; 2265 (21.6%) with a PCD and 8240 (78.4%) with a non‐PCD (percutaneous angioplasty balloon and/or bare metal stent). Survival rates at 2 years (77.4% versus 79.7%) and 3 years (70.7% versus 71.8%) were similar between PCD and non‐PCD groups, respectively. The adjusted hazard for all‐cause mortality for patients treated with a PCD versus non‐PCD was 1.06 (95% CI, 0.95–1.18, P =0.3013). Among patients who died between October 1, 2015, and December 31, 2017, the cause of death according to treatment group, PCD versus non‐PCD, was similar. CONCLUSIONS Among patients undergoing femoropopliteal peripheral endovascular intervention within the Veterans Administration Health Administration, there was no increased risk of long‐term, all‐cause mortality associated with PCD use. Cause‐specific mortality rates were similar between treatment groups. Nonstandard Abbreviations and Acronyms CDW corporate data warehouse CLI critical limb ischemia DCB drug‐coated balloon DES drug‐eluting stent NDI National Death Index PCD paclitaxel‐coated device PVI peripheral endovascular intervention VA Veterans Administration VHA Veterans Health Administration CLINICAL PERSPECTIVE What Is New? This work uses patient‐level data from the Veterans Administration Health Administration to evaluate the association between paclitaxel‐coated devices, long‐term mortality, and cause of death. Among patients undergoing femoropopliteal peripheral endovascular intervention, there was no increased risk of long‐term, all‐cause mortality associated with paclitaxel‐coated device use. Furthermore, cause‐specific mortality rates were similar between treatment groups. What Are the Clinical Implications? This postmarket surveillance study demonstrates that within the Veterans Health Administration, peripheral endovascular intervention with paclitaxel‐coated devices are not associated with an increased risk of long‐term, all‐cause mortality. The safety of paclitaxel‐coated devices (PCDs; such as drug‐coated balloon [DCB] or drug‐eluting stent [DES]) for peripheral endovascular intervention (PVI) among patients with lower extremity peripheral artery disease is unclear. A meta‐analysis and systematic review found the use of PCDs to be associated with increased mortality at 2 years and 4 to 5 years post‐PVI when compared with non‐PCDs (percutaneous angioplasty balloon and/or bare metal stent). 1 Contrary to these findings, subsequent large analyses of Centers for Medicare and Medicaid Services data did not observe an increased mortality signal among patients treated with PCDs compared with those treated with non‐PCDs. <su -Abstract Truncated-
cardiac & cardiovascular systems